JAMA Oncology (jama-oncology)
Journal positioning
JAMA Oncology is a JAMA Network specialty journal for clinical and translational
oncology research aimed at a broad cancer-care readership — medical, surgical, and
radiation oncologists, as well as cancer-epidemiology and outcomes researchers. It
favors practice-relevant work: randomized cancer trials, comparative-effectiveness and
real-world outcomes analyses, screening and prevention studies, and biomarker work tied
to a clinically meaningful endpoint. It is positioned as a general oncology venue with
JAMA's emphasis on absolute benefit, toxicity, and patient-centered outcomes, distinct
from a society flagship such as Annals of Oncology (ESMO). Single-arm early-phase
reports with no comparator, descriptive molecular series, and surrogate-only signals
with weak clinical translation are a weak fit. This skill is a fit /
venue-selection / re-framing aid; it is not clinical or regulatory advice and does
not replace the journal's current instructions for authors. Before submitting, re-check
the live JAMA Oncology author instructions.
When to trigger
- The author names JAMA Oncology for a clinical, epidemiologic, or outcomes oncology
study and wants a fit/framing check.
- A cancer study must be re-framed around a clinically meaningful survival, toxicity,
or quality-of-life endpoint for a broad oncology audience.
- The author is choosing between JAMA Oncology, JAMA, and a society or subspecialty
oncology journal (e.g., Annals of Oncology).
- The author needs the journal's reporting-guideline, registration, and desk-reject
expectations for oncology work.
Scope & topic fit
- Randomized oncology trials (phase 2/3) reporting survival, response, toxicity, or
patient-reported outcomes, including practice-de-escalation trials.
- Comparative-effectiveness and real-world-evidence studies using cancer registries,
claims, or institutional cohorts with rigorous confounding control.
- Cancer screening, early-detection, and prevention studies with clinically meaningful
endpoints and harms accounting.
- Prognostic and predictive biomarker studies validated against an outcome, not just
associated with a molecular feature.
- Health-services, disparities, financial-toxicity, and survivorship research in
oncology.
- Pooled analyses and meta-analyses answering a focused, decision-relevant cancer
question.
Method & evidence bar
- Trials must be adequately powered with a prespecified primary endpoint; overall
survival and validated surrogates are preferred, and surrogate-only endpoints need
explicit justification of clinical relevance.
- The applicable reporting guideline and checklist are required: CONSORT for trials,
STROBE for observational/registry studies, PRISMA for systematic reviews, REMARK-style
rigor for tumor-marker work.
- Trials require prospective registration; registration number, protocol, and
statistical-analysis plan are expected, including amendments.
- Survival analyses must report absolute differences, hazard ratios with confidence
intervals, and adequate follow-up; toxicity (graded per a standard scheme) must be
reported alongside efficacy.
- Real-world/registry claims must address immortal-time, selection, and indication bias;
causal language must match the design.
- Biomarker claims need a prespecified cut-point, an independent validation set, and
reporting of analytic performance.
Structure & house style
- JAMA Network format with a structured abstract and a Key Points box; re-check current
article types (Original Investigation, Brief Report, Research Letter, etc.) and limits
on the live guide.
- The introduction frames a focused, decision-relevant cancer question; the discussion
states the practice implication and net clinical benefit plainly.
- Tables/figures follow JAMA Network statistical-reporting standards; CONSORT/STROBE
flow diagrams, Kaplan-Meier curves with numbers at risk, and toxicity tables are
expected where applicable.
- Supplements carry the protocol, SAP, full toxicity and subgroup analyses, and
consort/biomarker checklists.
Official-submission checklist
- Before giving submission-ready advice, read
../../resources/source-basis.md and
../../resources/official-source-map.md; start from the ICMJE and JAMA Network
anchors, then cite the current JAMA Oncology page you checked.
- Search the live site for "JAMA Oncology instructions for authors" and follow the
current version.
- Re-check article types and word/reference/table limits, structured-abstract and Key
Points format, and the JAMA Network statistical-reporting requirements.
- Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA), the
data-sharing statement, and protocol/SAP submission.
- Re-check IRB/ethics and consent statements, ICMJE authorship and conflict-of-interest
disclosure (industry ties are scrutinized in oncology), funding, and AI-use disclosure.
- If the live official instructions conflict with this skill, the official instructions
win.
Pre-submission self-check
Common desk-reject triggers
- Single-arm early-phase reports with no comparator presented as practice-relevant.
- Surrogate-only endpoints (e.g., response rate, PFS) framed as definitive clinical benefit without justification.
- Registry/real-world analyses with immortal-time or indication bias and overstated causal claims.
- Biomarker associations with no prespecified cut-point or independent validation.
- Missing trial registration, protocol, or toxicity reporting alongside efficacy.
- Narrow molecular or subspecialty interest better served by a society or basic-science cancer journal.
Re-routing decision
- ESMO-society readership or European practice framing →
annals-of-oncology.
- Broadly practice-changing, top-tier cancer trial → general medicine (
jama / NEJM / The Lancet in the natural-science bundle).
- General internal-medicine relevance over oncology specialty →
jama-internal-medicine.
- Cancer imaging with an imaging-method core →
radiology.
- Surgical-oncology technique or perioperative focus →
jama-surgery.
Output format
[Fit] High / Medium / Low (one-line reason)
[Target] JAMA Oncology
[Specialty tags] <2–3 closest oncology topics>
[Study design / reporting guideline] <RCT-CONSORT / registry-STROBE / review-PRISMA / biomarker-REMARK>
[Method/evidence] <does power, endpoint, registration, and validation clear the bar?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / toxicity / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>